Print Share Email Send Email Your Name (required) Example: John Doe This field is required. Email Address (required) Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me This field is required. Please enter a valid email address. Recipient Email Address(es) (required - use a semicolon to separate multiple addresses) Separate multiple email address with semi-colons (up to 5). This field is required. Please enter a valid email address. One or more of your email addresses are invalid. Please review before submitting. Subject Subject for your email. Message (Maximum characters: 1,000) Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Malick WA, Koruth J. Malick W.A., & Koruth J Malick, Waqas A., and Jacob Koruth. EAST-AFNET4: Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. Hurst's the Heart Updates, 30 September 2020. McGraw-Hill, 2020. AccessMedicine. https://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=553247§ionid=250281115APA Citation Malick WA, Koruth J. Malick W.A., & Koruth J Malick, Waqas A., and Jacob Koruth. (2020). East-afnet4: early rhythm-control therapy in patients with atrial fibrillation. Fuster V. Fuster V Fuster, Valentin. Hurst's the heart updates. McGraw-Hill. https://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=553247§ionid=250281115.MLA Citation Malick WA, Koruth J. Malick W.A., & Koruth J Malick, Waqas A., and Jacob Koruth. "EAST-AFNET4: Early Rhythm-Control Therapy in Patients with Atrial Fibrillation." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. McGraw-Hill, 2020, https://accessmedicine.mhmedical.com/updatesContent.aspx?gbosid=553247§ionid=250281115. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content EAST-AFNET4: Early Rhythm-Control Therapy in Patients with Atrial Fibrillation by Waqas A. Malick, Jacob Koruth Listen + +Update to Chapter 83: Atrial Fibrillation, Atrial Flutter, and Atrial Tachycardia Study Summary + +The EAST-AFNET4 trial was designed to test whether or not early rhythm control, either through anti-arrhythmic drug therapy or atrial fibrillation (AF) ablation, would be associated with better outcomes in patients. A total of 2789 patients underwent randomization (at a mean time period of 36 days from the time of diagnosis): 1395 assigned to early rhythm control, and 1394 assigned to usual care. At 2 years, 82.1% of patients in the rhythm-control group and 60.5% of patients in the usual-care group were in sinus rhythm. The trial was stopped for efficacy after a median follow-up of 5.1 years. The primary outcome (death from cardiovascular causes, stroke [ischemic or hemorrhagic], or hospitalization with worsening of heart failure or acute coronary syndrome) occurred in 249 patients in the rhythm-control group whereas it occurred in 316 patients in the usual-care group (HR 0.79, 96% CI: 0.66-0.94), with significant reductions in both death (HR 0.72, CI 0.52-0.98) and stroke (HR 0.65, CI: 0.44-0.97) with early rhythm control (see accompanying Hurst's Central Illustration). Interestingly, the absolute risk reduction with rhythm control was 1.1%. More serious adverse events occurred in the rhythm-control group than in the usual-care group (4.9% versus 1.4%), mostly due to effects of antiarrhythmic drug therapy and procedural complications. Graphic Jump LocationView Full Size|Favorite Figure|Download Slide (.ppt) Commentary + +Study Strengths: EAST-AFNET4 is the first trial to demonstrate significant benefit of early rhythm control in patients with a new diagnosis of AF, with respect to both mortality and stroke reduction. Importantly, both groups in this trial had 90% of patients on anticoagulation at 2 years, indicating the importance of anticoagulation to reduced ischemic stroke rates. AF is a progressive disease that leads to adverse remodeling of the left atrium causing atrial cardiomyopathy and atrial functional mitral regurgitation. Therefore, EAST-AFNET4 suggests that early initiation of rhythm control may prevent atrial cardiomyopathy and improve outcomes. +Study Limitations: Significant limitations of the EAST-AFNET4 include its low event rates and attrition of follow-up, with 9.0% of patients lost to follow-up in the early-rhythm-control group and 6.6% in the usual-care group. Additionally, AF burden was not tracked, so the extent to which outcomes can be attributed to maintenance of sinus rhythm is unclear. +Next Steps/Clinical Perspective: In the AFFIRM Trial, there was no significant difference between rate and rhythm control with respect to mortality or stroke, but patients in the rate-control arm had fewer adverse events attributed to toxicities of antiarrhythmic therapy. However, in a post hoc analysis, the presence of sinus rhythm was significantly associated with a lower risk of death. Since then, there have been significant advancements in both AF ablation techniques and pharmacology to achieve rhythm control. The CABANA Trial showed lower risk of recurrence of AF with catheter ablation as well as a reduction in the composite end point of mortality or hospitalization for cardiovascular causes (HR 0.83, 95% CI 0.74-0.93) than antiarrhythmic drugs. Interestingly, in EAST-AFNET4, only 19% of patients underwent ablation for rhythm control. Further research is required to define optimal rhythm control strategies in patients with new onset AF. Trial Reference + + + +Kirchof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. doi:10.1056/NEJMoa2019422.